ArticleGigaScience2025
A sulfatide-centered ultra-high-resolution magnetic resonance MALDI imaging benchmark dataset for MS1-based lipid annotation tools.
Article in GigaScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MALDI Mass Spectrometry Imaging in Alzheimer's Disease Lipidomics: Matrix Selection, Spatial Lipid Pathology and Emerging Analytical Strategies.International journal of molecular sciences · 2026Review
- A sulfatide-centered ultra-high-resolution magnetic resonance MALDI imaging benchmark dataset for MS1-based lipid annotation tools.GigaScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSpatial omics techniques are indispensable for studying complex biological systems and for the discovery of spatial biomarkers. While several current matrix-assisted laser desorption/ionization mass spectrometry imaging (MSI) instruments are capable of localizing numerous metabolites at high spatial and spectral resolution, most MSI data are acquired at the MS1 level only. Assigning molecular identities based on MS1 data presents significant analytical and computational challenges, as the inherent limitations of MS1 data preclude confident annotations beyond the sum formula level.
resultsTo enable future advancements of computational lipid annotation tools, well-characterized benchmark-or ground-truth-datasets are crucial, which exceed the scope of synthetic data or data derived from mimetic tissue models. To this end, we provide 2 sulfatide-centered, biology-driven magnetic resonance MSI (MR-MSI) datasets at different mass resolving powers that characterize lipids in a mouse model of human metachromatic dystrophy. These data include an ultra-high-resolution (R ∼1,230,000) quantum cascade laser mid-infrared imaging-guided MR-MSI dataset that enables isotopic fine structure analysis and therefore enhances the level of confidence substantially. To highlight the usefulness of the data, we compared 118 manual sulfatide annotations with the number of decoy database-controlled sulfatide annotations performed in Metaspace (67 at a false discovery rate <10%).
conclusionsOverall, our datasets can be used to benchmark annotation algorithms, validate spatial biomarker discovery pipelines, and serve as a reference for future studies that explore sulfatide metabolism and its spatial regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.